Anti-VEGF agents for age-related macular degeneration

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 1, 2010, Pages 103-118

  Özkiris, Abdullah ^a  

^a ACIBADEM UNIVERSITY   (Turkey)

Author keywords

Age related macular degeneration; Anti VEGF agents

Indexed keywords

AFLIBERCEPT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANECORTAVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRANILIC ACID; BENAZEPRIL; BEVACIZUMAB; CAPTOPRIL; DIURETIC AGENT; ENALAPRIL MALEATE; ENALAPRILAT; ETANERCEPT; IMIDAZO[1,2 A]PYRIDINE DERIVATIVE; LISINOPRIL; MOEXIPRIL; NIFEDIPINE; PEGAPTANIB; QUINAPRIL; QUINAZOLINE DERIVATIVE; RAMIPRIL; RANIBIZUMAB; SMALL INTERFERING RNA; SOTALOL; SQUALAMINE; TRANDOLAPRIL; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; VASCULOTROPIN; VASODILATOR AGENT; VERTEPORFIN;

ADD ON THERAPY; ARTERIOSCLEROSIS; ARTERY OCCLUSION; ARTHRITIS; ASCITES; ASTHMA; ATHEROMA; AUTOIMMUNE DISEASE; BACKACHE; BLEEDING; BLINDNESS; BRAIN EDEMA; BRAIN TUMOR; CAPILLARY LEAK SYNDROME; CLINICAL TRIAL; COLON CANCER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG RESEARCH; ENDOMETRIOSIS; ENDOMETRIUM CARCINOMA; ENDOPHTHALMITIS; EYE DISEASE; GLOMERULONEPHRITIS; GLOMERULOPATHY; GOLD STANDARD; GRAFT REJECTION; HEALTH CARE QUALITY; HEMANGIOFIBROMA; HEMANGIOMA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; INJECTION SITE REACTION; INTRAOCULAR PRESSURE; IRIS DISEASE; KAPOSI SARCOMA; KIDNEY DISEASE; LASER COAGULATION; LIVER CIRRHOSIS; LYMPHEDEMA; METRORRHAGIA; NEOVASCULAR GLAUCOMA; NEPHROSCLEROSIS; NERVE INJURY; NONHUMAN; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PLEURA EFFUSION; PNEUMONIA; PREVALENCE; PSORIASIS; RACE DIFFERENCE; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; RETINA MACULA HEMORRHAGE; REVIEW; RHEUMATOID ARTHRITIS; SCAR FORMATION; SIDE EFFECT; SKIN EDEMA; STROKE; SUBRETINAL NEOVASCULARIZATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; UVEITIS; VISUAL DISORDER; VISUAL IMPAIRMENT;

AGED; ANGIOGENESIS INHIBITORS; ANIMALS; BLINDNESS; CLINICAL TRIALS AS TOPIC; HUMANS; MACULAR DEGENERATION; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 73649108258     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770902762885     Document Type: Review

References (70)

1. Bressler NM, Bressler SB, Congdon NG, et al. Age-Related Eye Disease Study Research Group: Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003;121:1621-1624
2. Friedman DS, O'Colmain BJ, Muñoz B, et al. Eye Diseases Prevalence Research Group: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572
3. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358:2606-2617
4. Chong EW, Kreis AJ, Wong TY, et al. Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysis. Arch Ophthalmol 2008;126:826-833
5. Hooper P, Jutai JW, Strong G, Russell-Minda E. Age-related macular degeneration and low-vision rehabilitation: a systematic review. Can J Ophthalmol 2008;43:180-187
6. Klein R. Overview of progress in the epidemiology of age-related macular degeneration. Ophthalmic Epidemiol 2007;14:184-187 (Pubitemid 47493722)
7. Klein R, Klein BE, Moss SE. Relation of smoking to the incidence of age-related maculopathy. The Beaver DamEye Study. Am J Epidemiol 1998;147:103-110 (Pubitemid 28060479)
8. Radimer KL, Subar AF, Thompson FE. Nonvitamin, nonmineral dietary supplements: issues and findings from NHANES III. J Am Diet Assoc 2000;100:447-454
9. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004;137:486-495
10. Edwards AO, Ritter R, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421-424
11. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308:419-421
12. Hageman GS, Anderson DH, Johnson LV. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005;102:7227-7232
13. Jakobsdottir J, Conley YP, Weeks DE, et al. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet 2005;77:389-407
14. Gold B, Merriam JE, Zernant J. Variation in factor B (BF) and complement component 2 (C2)genes is associated with age-related macular degeneration. Nat Genet 2006;38:458-462
15. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res 2001;73:887-896
16. Esparza-Gordillo J, Soria JM, Buil A, et al. Genetic and environmental factors influencing the human factor H plasma levels. Immunogenetics 2004;56:77-82
17. Thornton J, Edwards R, Mitchell P, et al. Smoking and age-related macular degeneration: a review of association. Eye 2005;19:935-944
18. Sangiovanni JP, Chew EY, Clemons TE, et al. The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20. Arch Ophthalmol 2007;125:671-679
19. Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. Arch Ophthalmol 2006;124:995-1001
20. Clemons TE, Milton RC, Klein R, et al. Age-related Eye Disease Study. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-1436
21. Chen J, Fitzke F, Pauleikhoff D, Bird A. Functional loss in age-related Bruch's membrane change with choroidal perfusion defect. Invest Ophthalmol Vis Sci 1992;33:334-340
22. Ciulla TA. Evolving pathophysiological paradigms for age related macular degeneration. Br J Ophthalmol 2001;85:510-512
23. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007;18:502-508
24. Pasqualetti G, Danesi R, Del Tacca M, Bocci G. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics 2007;8:49-66
25. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol 1994;112:500-509
26. Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (Tap) Study Group: photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two year results of 2 randomized clinical trials-TAP report no. 2. Arch Ophthalmol 2001;119:198-207
27. Arnold JJ, Blinder KJ, Bressler NM, et al. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: Case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol 2004;137:683-696
28. Michels S, Schmidt-Erfurth U. Photodynamic therapy with verteporfin: a new treatment in ophthalmology. Semin Ophthalmol 2001;16:201-216
29. Azab M, Boyer DS, Bressler NM, et al. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-457
30. Bressler NM. Verteporfin in Photodynamic Therapy Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-560
31. Eter N, Vogel A, Inhetvin-Hutter C, Spitznas M. Interval reduction of photodynamic therapy (PDT) in age-related macular degeneration (AMD) is not advantageous. A pilot project. Ophthalmologe 2003;100:314-317
32. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (Tap) Study Group: photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP Report 1. Arch Ophthalmol 1999;117:1329-1345
33. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-304 (Pubitemid 40202568)
34. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: One-year results. Arch Ophthalmol 2003;121:667-673
35. Schmidt-Erfurth U, Michels S, Augustin A. Perspectives on verteporfin therapy combined with intravitreal corticosteroids. Arch Ophthalmol 2006;124:561-563
36. Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 2005;40:63-68
37. Brown MM, Brown GC, Brown H. Value-based medicine and interventions for macular degeneration. Curr Opin Ophthalmol 2007;18:194-200
38. Gragoudas ES, Adamis AP, Cunningham JR, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816
39. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69:11-16
40. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047
41. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511
42. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372
43. Van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005;293:1509-1513
44. LUCENTIS [package insert] : South San Francisco, CA: Genentech Inc. 2006
45. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.Invest Ophthalmol Vis Sci 2005;46:726-733
46. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group: ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431
47. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.Am J Ophthalmol 2008;145:239-248
48. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144:850-857
49. Giantonio BJ, Levy DE, O'Dwyer PJ, et al. Eastern ooperative Oncology Group. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Ann Oncol 2006;17:1399-1403
50. Miskala PH, Bass EB, Bressler NM, et al. Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no. 12. Ophthalmology 2004;111:1981-1992
51. coll GE, Sparrow JR, Marinovic A, et al. Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage. Retina 1995;15:319-326
52. Stifter E, Michels S, Prager F, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol 2007;144:886-892
53. Meyer CH, Scholl HP, Eter N, et al. Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol 2008;86:490-494
54. D'Amico DJ, Goldberg MF, Hudson H, et al. Anecortave Acetate Clinical Study Group: anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 2003;23:14-23
55. Raju TN. The Nobel chronicles, 1978. Lancet 1999;354:1567
56. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. PNAS 2002;99:11393-11398
57. Genentech, Inc. US2008226629; 2008
58. Kyowa Hakko Kogyo KK. US20060277121; 2008
59. Regeneron Pharma. WO2006086544; 2007
60. Csl Ltd. WO2007AU00799; 2007
61. Regeneron Pharma. KR20067000521; 2006
62. Astrazeneca AB. US20040566841; 2007
63. Lilly Co. EP20060735794; 2008
64. Bayer Schering Pharma AG. CN20058038187; 2007
65. Novartis AG. AU20020351909; 2007
66. Novartis AG. RU20020121645; 2007
67. Childrens Medical Center. NZ535670; 2006
68. Schering AG. WO2006EP02342; 2006
69. Cti Europ Srl. US20050517805; 2006
70. Methylgene Inc. EP20060851548; 2008